ATRA
Atara Biotherapeutics, Inc.
There isn't enough reported data to score ATRA yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ATRA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
ATRA's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ATRA PE Valuation
ATRA has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
ATRA Forward outlook
There aren't enough analyst estimates for ATRA to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ATRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$25.53 | +$44.22 |
| Q2 2024 | -$39.10 | +$34.65 |
| Q1 2024 | -$53.00 | -$0.75 |
| Q4 2023 | -$65.25 | -$9.25 |
| Q3 2023 | -$69.75 | -$8.00 |
| Q2 2023 | -$73.75 | -$10.00 |
| Q1 2023 | -$52.25 | +$38.75 |
| Q4 2022 | -$56.00 | +$34.75 |
NVO has the stronger earnings trend. Trailing diluted EPS is down 106% for ATRA versus NVO up 4.9%.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
ATRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2M | -65% |
| Q2 2026 | $630K | -96% |
| Q1 2026 | $516K | -99% |
| Q4 2025 | $1.6M | -95% |
| Q3 2025 | $3.5M | -91% |
| Q2 2025 | $17.6M | -39% |
| Q1 2025 | $98.1M | +259% |
| Q4 2024 | $32.8M | +670% |
ATRA's revenue has slid since its 2025 peak: $1M last quarter, down 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -243% | -139 points |
| Q2 2026 | -749% | -767 points |
| Q1 2026 | -653% | -692 points |
| Q4 2025 | -161% | -123 points |
| Q3 2025 | -104% | -49 points |
| Q2 2025 | 18% | +82 points |
| Q1 2025 | 40% | +154 points |
| Q4 2024 | -37% | +1373 points |
ATRA's operating margin was −243% last quarter, down 139 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over ATRA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ATRA on profitability, with a higher operating margin.
ATRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$879K | +$8.9M |
| Q2 2026 | -$3.3M | +$4M |
| Q1 2026 | -$3.1M | +$25.1M |
| Q4 2025 | -$5.7M | +$18.9M |
| Q3 2025 | -$9.8M | -$5.8M |
| Q2 2025 | -$7.3M | +$3.4M |
| Q1 2025 | -$28.1M | +$1.6M |
| Q4 2024 | -$24.6M | +$25.9M |
ATRA has burned cash in almost every quarter: −$13M over the past year, against −$70M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ATRA on cash generation, producing positive trailing cash flow while its opponent burns cash.
ATRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +293K shares |
| 1 year | +25% | +3M shares |
| 3 years | +269% | +11.2M shares |
| 5 years | +319% | +11.7M shares |
| Available history | +647% | +13.3M shares |
ATRA has 15M diluted shares, up 25% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ATRA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ATRA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -1.4x | Net Cash |
ATRA has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ATRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 12.7 | Oversold |
ATRA's weekly RSI is 44 (neutral) and its Stochastic is 13 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ATRA PE vs Healthcare Sector
ATRA has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ATRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.67 | 8.5% below |
| 20 week MA | $8.98 | 12% below |
| 50 week MA | $8.74 | 9.3% below |
| 100 week MA | $9.48 | 16% below |
| 200 week MA | $21.2 | 63% below |
ATRA is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over ATRA on trend strength, trading above more of its moving averages.
ATRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $412.8 | $554.5 | +34% |
| 2021 | $554.5 | $432.8 | -22% |
| 2022 | $432.8 | $74.8 | -83% |
| 2023 | $74.8 | $12.8 | -83% |
| 2024 | $12.8 | $12.2 | -5.2% |
| 2025 | $12.2 | $17.3 | +42% |
| 2026 YTD | $17.3 | $7.93 | -54% |
ATRA has finished lower in four of the last six years. It's down 54% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over ATRA on returns for 2026, with the stronger performance.